Androgen receptor in salivary gland carcinoma: A review of an old marker as a possible new target |
| |
| Authors: | Chit Cheng Yeoh Nedal Dabab Elyse Rigby Ritu Chhikara Iolia Akaev Ricardo Santiago Gomez Felipe Fonseca Peter A. Brennan Siavash Rahimi |
| |
| Affiliation: | 1. Department of Oncology, Queen Alexandra Hospital, Portsmouth, UK;2. Pathology Centre‐Histopathology, Queen Alexandra Hospital, Portsmouth, UK;3. School of Pharmacy and Biomedical Science, University of Portsmouth, Portsmouth, UK;4. Department of Oral Surgery and Pathology, School of Dentistry, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil;5. Department of Oral and Maxillofacial Surgery, Queen Alexandra Hospital, Portsmouth, UK |
| |
| Abstract: | The role of the androgen receptor (AR) as an immunomarker for diagnosis of salivary gland duct carcinoma (SDC) is well known. Other non‐squamous cell head and neck cancers (NSCC‐HN), including a small subset of salivary gland cancers (SGCs), can also express AR. With the increase in effective and powerful new generation of anti‐androgen agents and drugs administered orally, more targetable AR‐driven NSCC‐HN, such as subsets of SGCs, should be investigated for possible expression of AR. In this review, we focus on SGC subtypes, which could express AR and describe the main androgen deprivation therapy (ADT) strategies. |
| |
| Keywords: | abiraterone androgen receptor enzalutamide head and neck immunohistochemistry non‐squamous cell carcinoma salivary gland carcinoma |
|
|
